Novoprotein Scientific Inc. (SHA:688137)
China · Delayed Price · Currency is CNY 51.62
-2.26 (-4.19%)
At close: May 12, 2026
Novoprotein Scientific Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -76.58 | -77.78 | -54.42 | 12.84 | 90.72 | 149.01 |
Depreciation & Amortization | 29.92 | 29.92 | 31.32 | 22.55 | 20.46 | 9.2 |
Other Amortization | 2.52 | 2.52 | 6.11 | 1.58 | 1.38 | 0.78 |
Loss (Gain) From Sale of Assets | -0.73 | -0.73 | -0.14 | -0 | -0.04 | -0.03 |
Asset Writedown & Restructuring Costs | 33.03 | 33.03 | 6.7 | 0.09 | 0.08 | 0.15 |
Loss (Gain) From Sale of Investments | -0.27 | -0.27 | -2.76 | -17.19 | -4.16 | -0.85 |
Provision & Write-off of Bad Debts | - | - | 2.09 | -1.58 | 1.22 | 3.9 |
Other Operating Activities | -25.13 | -23.12 | 4.48 | 36.9 | 19.63 | 15.17 |
Change in Accounts Receivable | 1.22 | 1.22 | 14.64 | 62.8 | -57.73 | -52.73 |
Change in Inventory | -12.61 | -12.61 | -14.81 | -41.26 | -51.84 | -30.96 |
Change in Accounts Payable | 14.71 | 14.71 | 10.76 | -8.62 | -15.18 | -29.11 |
Change in Other Net Operating Assets | 12.33 | 12.33 | 12.63 | 10.48 | 7.01 | 7 |
Operating Cash Flow | -14.17 | -13.36 | 13.32 | 69.16 | 3.38 | 70.97 |
Operating Cash Flow Growth | - | - | -80.75% | 1948.16% | -95.24% | -27.26% |
Capital Expenditures | -78.17 | -78.89 | -44.88 | -44.94 | -36.77 | -69.95 |
Sale of Property, Plant & Equipment | 0 | 0 | 0 | 0.01 | 0.01 | 0 |
Investment in Securities | 181.79 | 150.01 | -129.34 | -56.6 | -963.3 | 25 |
Other Investing Activities | 25.67 | 31.02 | 16.15 | 20.11 | 0.6 | 1 |
Investing Cash Flow | 129.29 | 102.14 | -158.06 | -81.42 | -999.45 | -43.95 |
Long-Term Debt Repaid | - | - | -26.5 | -17.32 | -11.34 | -4.85 |
Total Debt Repaid | - | - | -26.5 | -17.32 | -11.34 | -4.85 |
Net Debt Issued (Repaid) | - | - | -26.5 | -17.32 | -11.34 | -4.85 |
Issuance of Common Stock | - | - | - | - | 1,742 | 117.67 |
Repurchase of Common Stock | - | - | -10.35 | - | - | - |
Common Dividends Paid | - | - | -35.09 | -35.09 | - | -16.29 |
Other Financing Activities | -27.98 | -23.83 | -0.63 | -1.52 | 2.51 | -2 |
Financing Cash Flow | -27.98 | -23.83 | -72.56 | -53.93 | 1,733 | 94.53 |
Foreign Exchange Rate Adjustments | -1.9 | -1.13 | 0.62 | 0.54 | 2.64 | -0.79 |
Net Cash Flow | 85.24 | 63.82 | -216.69 | -65.65 | 739.94 | 120.75 |
Free Cash Flow | -92.34 | -92.25 | -31.57 | 24.22 | -33.39 | 1.02 |
Free Cash Flow Growth | - | - | - | - | - | -98.82% |
Free Cash Flow Margin | -61.46% | -62.99% | -24.75% | 15.81% | -12.62% | 0.30% |
Free Cash Flow Per Share | -1.31 | -1.32 | -0.45 | 0.34 | -0.58 | 0.03 |
Cash Income Tax Paid | 9.77 | 11.27 | 15.27 | 2.63 | 58.63 | 71.24 |
Levered Free Cash Flow | 110.03 | -1,067 | -21.19 | 0.36 | -68.42 | -40.11 |
Unlevered Free Cash Flow | 110.03 | -1,067 | -18.95 | 2.6 | -65.89 | -38.99 |
Change in Working Capital | 23.07 | 23.07 | 19.94 | 13.97 | -125.93 | -106.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.